Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, multicenter, phase II trial comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer (Neo-peaks study)

Next Previous
Search
Trial Profile

A randomized, multicenter, phase II trial comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer (Neo-peaks study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Letrozole; Tamoxifen; Trastuzumab emtansine
  • Indications Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms Neo-peaks

Most Recent Events

  • 30 Jul 2021 Status changed from active, no longer recruiting to completed.
  • 12 Oct 2017 A total of 206 patients were enrolled (Aug 2014-Feb 2016), according to results presented at the 42nd European Society for Medical Oncology Congress.
  • 12 Sep 2017 Results (n=204) comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer, were presented at the 42nd European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top